Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Infosys Invests ₹8.3 Crores in Precision Oncology Startup 4baseCare to Drive Innovation in Healthcare

NextEdge Admin

14 Dec 2024

2 min 8 sec

4baseCare,cancer diagnosis,AI and analytics

Infosys, the IT services giant, announced an investment of ₹8.3 crores (approximately USD 1 million) in 4baseCare, a healthcare and life sciences startup, through the Infosys Innovation Fund. This strategic partnership aims to leverage 4baseCare’s expertise in precision oncology to co-create innovative solutions for Infosys’ clients, driving their business transformation.

4baseCare specializes in developing advanced precision oncology solutions that integrate genomics and next-generation digital health technologies to deliver personalized cancer care. By harnessing diverse genomic and clinical datasets, 4baseCare employs AI and analytics to enhance cancer diagnosis, treatment, and drug discovery, offering transformative potential for the healthcare and life sciences sector.

Infosys, through its Innovation Fund, seeks to collaborate with AI and deep-tech startups like 4baseCare to strengthen its technological capabilities and foster next-generation solutions. The partnership aligns with Infosys’ vision to harness innovation in addressing complex challenges across industries, especially in healthcare. According to Infosys, the population-specific datasets generated by 4baseCare’s solutions hold immense potential to improve patient outcomes and advance drug development.

The investment represents a minority stake, capped at 20% of 4baseCare’s outstanding share capital. This collaboration underscores Infosys’ commitment to enabling breakthroughs in precision medicine while expanding its footprint in the rapidly evolving life sciences ecosystem. Together, Infosys and 4baseCare aim to drive meaningful innovation that improves patient lives globally.